Sprint Bioscience Q2 2022: Several potential catalysts on the horizon - Redeye

Redeye comments on Sprint’s Q2 2022 report, which aligned with our expectations. Overall, we judge that the company’s internal and external portfolios are progressing well, with several potential catalysts on the horizon.

Länk till analysen i sin helhet: https://www.redeye.se/research/853074/sprint-bioscience-q2-2022-several-potential-catalysts-on-the-horizon?utm_source=finwire&utm_medium=RSS